Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
- PMID: 20671765
- DOI: 10.1038/nrd3184
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Abstract
The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events. Because PLK1 has been preclinically validated as a cancer target, small-molecule inhibitors of PLK1 have become attractive candidates for anticancer drug development. Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumour suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals. In this article, recent insights into the biology of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-molecule PLK1 inhibitors will be examined.
Similar articles
-
Non-mitotic functions of polo-like kinases in cancer cells.Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188467. doi: 10.1016/j.bbcan.2020.188467. Epub 2020 Nov 7. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33171265 Review.
-
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.Expert Opin Drug Discov. 2015 Jan;10(1):1-8. doi: 10.1517/17460441.2015.962510. Epub 2014 Sep 29. Expert Opin Drug Discov. 2015. PMID: 25263688
-
The role of Plk3 in oncogenesis.Oncogene. 2016 Jan 14;35(2):135-47. doi: 10.1038/onc.2015.105. Epub 2015 Apr 27. Oncogene. 2016. PMID: 25915845 Review.
-
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).Expert Opin Ther Pat. 2024 Sep;34(9):789-806. doi: 10.1080/13543776.2024.2379924. Epub 2024 Jul 15. Expert Opin Ther Pat. 2024. PMID: 38994687 Review.
-
PLK1 as an oncology target: current status and future potential.Drug Discov Today. 2011 Jul;16(13-14):619-25. doi: 10.1016/j.drudis.2011.05.002. Epub 2011 May 13. Drug Discov Today. 2011. PMID: 21601650 Review.
Cited by
-
Volasertib for AML: clinical use and patient consideration.Onco Targets Ther. 2015 Jul 17;8:1761-71. doi: 10.2147/OTT.S60762. eCollection 2015. Onco Targets Ther. 2015. PMID: 26229484 Free PMC article. Review.
-
Overexpression of PLK1 relieved the myocardial ischemia-reperfusion injury of rats through inducing the mitophagy and regulating the p-AMPK/FUNDC1 axis.Bioengineered. 2021 Dec;12(1):2676-2687. doi: 10.1080/21655979.2021.1938500. Bioengineered. 2021. PMID: 34115550 Free PMC article.
-
In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Cancer Biol Ther. 2013 Jul;14(7):648-57. doi: 10.4161/cbt.25087. Epub 2013 May 31. Cancer Biol Ther. 2013. PMID: 23792639 Free PMC article.
-
Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.Oncol Rep. 2016 Jul;36(1):49-56. doi: 10.3892/or.2016.4820. Epub 2016 May 18. Oncol Rep. 2016. PMID: 27220401 Free PMC article.
-
Microarray gene expression profiling in colorectal (HCT116) and hepatocellular (HepG2) carcinoma cell lines treated with Melicope ptelefolia leaf extract reveals transcriptome profiles exhibiting anticancer activity.PeerJ. 2018 Jul 18;6:e5203. doi: 10.7717/peerj.5203. eCollection 2018. PeerJ. 2018. PMID: 30042885 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous